Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Significant Drop in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 1,265 shares, a decrease of 83.0% from the November 30th total of 7,424 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 165,012 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 165,012 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

Enzon Pharmaceuticals Trading Up 0.5%

Shares of OTCMKTS ENZN traded up $0.00 during mid-day trading on Friday, reaching $0.04. 4,546 shares of the company’s stock were exchanged, compared to its average volume of 58,108. The business has a fifty day simple moving average of $0.05 and a 200 day simple moving average of $0.07. Enzon Pharmaceuticals has a twelve month low of $0.03 and a twelve month high of $0.23. The firm has a market capitalization of $3.15 million, a price-to-earnings ratio of -0.85 and a beta of 0.12.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.